This site uses cookies to enhance your browsing experience. By continuing navigation, you agree to the use of cookies. For more information about our use of cookies, see our Privacy Policy.

Proactive.
Comprehensive.
Engaging.

Advancing the Treatment of Heart Failure. Together.

Endotronix is committed to improving care 
for people living with heart failure.

ENDOTRONIX IS AN EDWARDS LIFESCIENCES COMPANY.

Meet Tom

A Cordella patient who is able to embrace life again

The Evidence is in

Cordella is clinically proven to enable better heart failure management.2

Markedly low 6-month HFH/
all-cause mortality rate (0.159)*

Significant improvement in key quality of life metrics and functional capacity (KCCQ & 6-minute walk test)

Reduction in HFH/all-cause mortality rate of PA pressure-guided HF management group vs. former control group*

*Datapoints from the FDA Summary of Safety and Effectiveness Data (SSED) varied slightly due to a change in statistical analysis from published PROACTIVE-HF results (0.15 & 44%).

HFH: Heart Failure Hospitalizations; DSRC: Device or System-Related Complications; KCCQ: Kansas City Cardiomyopathy Questionnaire

Cordella is now FDA Approved

Heart failure (HF) is a debilitating, progressive disease that impacts everyday life.

  • 1 in 4 people will develop HF during their lifetime3
  • Climbing HF-related mortality rates4
  • After 65 the risk of HF increases dramatically5
  • Only 9.1% of HFrEF patients achieve optimal guideline-directed medical therapy (GDMT)6,7

It’s time to lead a more full and active life.

Learn about Cordella.

of Cordella patients believe PA pressure monitoring & care has a positive health impact8

“[Cordella] is an amazing device. It’s a tool that everyone should have access to. It is the future of medicine in our minds.”

–Anita, Caregiver of a Cordella patient

What's New

References

  1. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032. doi: 10.1161/CIR.0000000000001063.
  2. Guichard JL et al. J Am Coll Cardiol HF. 2024 Aug 2:S2213-1779(24)00485-2.
  3. Bozkurt B et al.  J Card Fail. 2023 Oct;29(10):1412-1451.
  4. Sayed A et al. JAMA Cardiol. 2024 Jun 1;9(6):585-589.
  5. HF Facts & Information. Heart Failure Society of America. https://hfsa.org/patient-hub/heart-failure-facts-information. Last accessed Oct 25, 2023.
  6. Mentias A et al. JACC Heart Fail. 2023 Oct 26:S2213-1779(23).
  7. Optimal triple GDMT was defined as ≥50% of the target daily dose of beta-blockers, ≥50% of the target daily dose of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker or any dose of sacubitril/valsartan, and any dose of mineralocorticoid receptor antagonist.
  8. Guichard JL et al. Presented at THT 2023.
⚠️ Important Risk Information
Top